[ @entity972 -sparing effect of XXXX in a 3-component combination preparation for the therapy of @entity101 ].

@entity1 @entity1760 @entity101 @entity3592 @entity1372 @entity551 @entity44487 @entity972 @entity1011 @entity414 @entity73157 @entity9355
A new fixed-dose combination drug, @entity73157 (1 film-coated tablet contains 120 mg @entity44487 , 2.5 mg @entity3592 and 25 mg @entity9355 ) was tested in a long-term study. 20 @entity1 with mild to moderate primary @entity101 were treated for 6 months. Items of investigation were: influence on low range serum @entity972 , influence on serum @entity1760 concentration, blood pressure lowering effect, tolerance and side effects. Initial dosage of 1 tablet b.i.d. could be reduced to 1 tablet in the morning in 4 @entity1 . The mean serum @entity972 concentration rose from 3.79 +/- 0.3 mmol/l to 4.15 +/- 0.55 mmol/l (p less than 0.01) after 4 weeks, and to 4.26 +/- 0.37 mmol/l (p less than 0.001) after 6 months of treatment, all single values remaining within normal limits. The serum @entity1760 concentration rose to a small, insignificant extent. @entity551 were lowered highly significantly from 177 +/- 12/103 +/- 7 mm Hg by 19/11 mm Hg. The mean values were within normal limits (less than 160/95 mm Hg) after treatment. Heart rate fell simultaneously by 11 beats per minute, on average (p less than 0.01). Atrioventricular conduction time was slightly prolonged in 2 cases. Serum levels of @entity1372 , BUN and @entity1011 rose slightly, but remained within the normal range during treatment. @entity414 and lipids were not influenced significantly. 1 @entity1 complained of transient gastrointestinal discomfort. Generally the drug was tolerated very well.
